World’s leading biobanks join a global network to advance personalized healthcare research

6 Apr 2020

The platform enables collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

BC Platforms, the provider of a powerful data and technology platform for personalized healthcare, has added three new leading biobanks to its Global Data Partner Network, BCRQUEST.com: Generation Scotland (UK), Bialystok Biobank (Poland) and Biobank Graz (Austria).

World’s leading biobanks join a global network to advance personalized healthcare research

The BCRQUEST.com platform enables researchers to efficiently access harmonized data while strictly adhering to global and local data privacy and security regulations.

The platform and its supporting framework facilitate collaboration between pharmaceutical institutions, healthcare and academic researchers to generate valuable insights and advance medical research.

The addition of these three new, high-quality biobanks brings the BCRQUEST.com network to almost 3.5 million consented patient healthcare records from nearly 10 countries in North America and Europe.

Bialystok Biobank focuses on clinical samples for cancer and specifically on new biomarkers for early diagnosis, as well as personalized therapy of cancer-based on genetic-molecular disorders.

Biobank Graz is one of the biggest biobanks in the world with 20 million tissue, blood and DNA samples from more than 1.2 million patients.

Generation Scotland is a population-based cohort designed to study the genetic and environmental determinants of health.

Dr Christian Gülly, COO, Biobank Graz, Medical University of Graz, Austria, commented: “We are excited to be collaborating with BC Platforms to securely share our data for the benefit of patients without compromising any privacy issues. We have been impressed by the BCRQUEST.com platform and its ability to analyse, integrate and share data in a secure manner and in line with the European General Data Protection Regulation (GDPR) to support researchers in developing personalized medicines.”

Given BC Platforms' strong focus on genetic and clinical data, Tero Silvola, CEO of BC Platforms described their growing network as a "unique" and "invaluable asset" for researchers and industry. Speaking of the new addition, he said: "This will progress the development of personalized healthcare for the benefit of patients, healthcare systems and research.”

Read More

Related news

HKBU scientists develop technique to eliminate drug side effects

HKBU scientists develop technique to eliminate drug side effects

19 May 2020

The novel method paves the way towards the mass production of affordable therapeutic drugs that are made with recyclable materials.

Read more 
Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

Vibalogics agrees to additional manufacturing for lead COVID-19 vaccine candidate of J&J unit

18 May 2020

CDMO is contracted to produce multiple clinical batches from German facility

Read more 
Characterizing virus and virus-like particles

Characterizing virus and virus-like particles

12 May 2020

New application study describes the separation and characterisation of adeno associated virus serotypes by AF4.

Read more 
AI technology company launches with Novartis and Sarepta deals

AI technology company launches with Novartis and Sarepta deals

11 May 2020

Collaborations focus on gene therapies for serious eye and muscle diseases using Dyno’s CapsidMap artificial intelligence platform to design AAV vectors.

Read more 
Bio-Rad launches anti-certolizumab pegol antibodies

Bio-Rad launches anti-certolizumab pegol antibodies

5 May 2020

Using this critical antibody reagent at the preclinical stage of development will minimize the need to revalidate assays with different reagents at the clinical development stage.

Read more 
BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

BERG named visionary in first-ever Frost Radar AI in Drug Discovery report

13 Apr 2020

The biotech pioneer is one of the first companies to develop corporate partnerships in this application of artificial intelligence (AI) for drug discovery.

Read more 
AstraZeneca incredibly excited by lung cancer treatment trial

AstraZeneca "incredibly excited" by lung cancer treatment trial

13 Apr 2020

Independent Data Monitoring Committee (IDMC) recommends unblind Phase III trial of Tagrisso 2 years ahead of schedule.

Read more 
German pharma companies are meeting the corona stress test

German pharma companies are meeting the corona "stress test"

7 Apr 2020

The head of the leading German pharmaceutical industry organization says German firms are working top-speed to find coronavirus medications.

Read more 
Servier strengthens its R&D pipeline with Symphogen acquisition

Servier strengthens its R&D pipeline with Symphogen acquisition

6 Apr 2020

Symphogen becomes the antibody center of excellence within Servier.

Read more 
Evotec expands into gene therapy with new Austrian unit

Evotec expands into gene therapy with new Austrian unit

6 Apr 2020

Evotec has established a dedicated gene therapy-based R&D site in Orth an der Donau, Austria with the immediate focus of spearheading a partnership with Japan’s Takeda to support its research projects, the German drug discovery firm said Monday.

Read more